Debby Van Dam

List of Publications by Year
in descending order

123 papers	6,087 citations	87723 38 h-index	79541 73 g-index
127 all docs	127 docs citations	127 times ranked	10214 citing authors

#	Article	IF	Citations
1	Age-related cognitive decline in spatial learning and memory of C57BL/6J mice. Behavioural Brain Research, 2022, 418, 113649.	1.2	14
2	Short-Term Pharmacological Induction of Arterial Stiffness and Hypertension with Angiotensin II Does Not Affect Learning and Memory and Cerebral Amyloid Load in Two Murine Models of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 2738.	1.8	1
3	Inflammation, Nitro-Oxidative Stress, Impaired Autophagy, and Insulin Resistance as a Mechanistic Convergence Between Arterial Stiffness and Alzheimerâ€™s Disease. Frontiers in Molecular Biosciences, 2021, 8, 651215.	1.6	16
4	Serum Corticosterone and Insulin Resistance as Early Biomarkers in the hAPP23 Overexpressing Mouse Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6656.	1.8	11
5	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation1. Journal of Alzheimer's Disease, 2021, 81, 1505-1527.	1.2	14
6	Altered stress hormone levels affect in vivo vascular function in the hAPP23+/- overexpressing mouse model of Alzheimer's disease. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H905-H919.	1.5	2
7	5-HT7 receptors in Alzheimer's disease. Neurochemistry International, 2021, 150, 105185.	1.9	12
8	How does a researcher choose the best rodent model for their Alzheimerâ€™s disease drug discovery study?. Expert Opinion on Drug Discovery, 2020, 15, 269-271.	2.5	1
9	Pentylenetetrazole-induced Seizure Susceptibility in the Tau58/4 Transgenic Mouse Model of Tauopathy. Neuroscience, 2020, 425, 112-122.	1.1	12
10	Progressive tau aggregation does not alter functional brain network connectivity in seeded hTau.P301L mice. Neurobiology of Disease, 2020, 143, 105011.	2.1	9
11	Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils. BMC Molecular and Cell Biology, 2020, 21, 81.	1.0	3
12	Neuroimaging of Subacute Brain Inflammation and Microstructural Changes Predicts Long-Term Functional Outcome after Experimental Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 768-788.	1.7	32
13	Alzheimerâ€™s disease: Neurotransmitters of the sleep-wake cycle. Neuroscience and Biobehavioral Reviews, 2019, 105, 72-80.	2.9	29
14	Sleep architecture changes in the APP23 mouse model manifest at onset of cognitive deficits. Behavioural Brain Research, 2019, 373, 112089.	1.2	18
15	Intrathecal cerebrospinal fluid infusion as a potential therapeutic strategy for Alzheimerâ€™s disease. Medical Hypotheses, 2019, 122, 57.	0.8	0
16	Alzheimer's disease and glaucoma: Lookâ€alike neurodegenerative diseases. Alzheimer's and Dementia, 2019, 15, 600-601.	0.4	7
17	Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice. Vascular Pharmacology, 2019, 118-119, 106561.	1.0	14
18	PTZ-induced seizures in mice require a revised Racine scale. Epilepsy and Behavior, 2019, 95, 51-55.	0.9	129

#	Article	IF	Citations
19	Evaluating the applicability of mouse SINEs as an alternative normalization approach for RT-qPCR in brain tissue of the APP23 model for Alzheimerâ€™s disease. Journal of Neuroscience Methods, 2019, 320, 128-137.	1.3	6
20	The validation of Short Interspersed Nuclear Elements (SINEs) as a RT-qPCR normalization strategy in a rodent model for temporal lobe epilepsy. PLoS ONE, 2019, 14, e0210567.	1.1	6
21	Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis. Vascular Pharmacology, 2019, 113, 70-76.	1.0	24
22	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. Journal of Parkinson's Disease, 2018, 8, 71-84.	1.5	12
23	Fibromyalgia as a glymphatic overload syndrome. Medical Hypotheses, 2018, 115, 17-18.	0.8	4
24	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 172-181.	1.2	16
25	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to earlyâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 99-111.	1.2	9
26	Sleep and Alzheimer's disease: A pivotal role for the suprachiasmatic nucleus. Sleep Medicine Reviews, 2018, 40, 17-27.	3.8	71
27	The First Histologic Evidence of a Paravascular Pathway Within the Optic Nerve. , 2018, 59, 1717.		10
28	Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?. Medical Hypotheses, 2018, 118, 98-102.	0.8	11
29	Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes. Frontiers in Neuroscience, 2018, 12, 185.	1.4	32
30	Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo. Journal of Alzheimer's Disease, 2018, 65, 265-281.	1.2	32
31	Letter to the Editor. Low ICP and normal tension glaucoma: optic nerve damage due to barotraumatic factors, failure of CSF dynamics, or both?. Journal of Neurosurgery, 2018, 129, 1100-1103.	0.9	0
32	Alzheimer's disease and glaucoma: can glymphatic system dysfunction underlie their comorbidity?. Acta Ophthalmologica, 2017, 95, e244-e245.	0.6	8
33	Progressive Motor Deficit is Mediated by the Denervation of Neuromuscular Junctions and Axonal Degeneration in Transgenic Mice Expressing Mutant (P301S) Tau Protein. Journal of Alzheimer's Disease, 2017, 60, S41-S57.	1.2	21
34	Accelerated high-frequency repetitive transcranial magnetic stimulation enhances motor activity in rats. Neuroscience, 2017, 347, 103-110.	1.1	19
35	Impaired hypoxic tolerance in <scp>APP</scp>23 mice: a dysregulation of neuroprotective globin levels. FEBS Letters, 2017, 591, 1321-1332.	1.3	7
36	Immune hyperreactivity of AÎ² plaque-associated microglia in Alzheimer's disease. Neurobiology of Aging, 2017, 55, 115-122.	1.5	205

#	Article	IF	Citations
37	Behavioural characterization of AnkyrinG deficient mice, a model for ANK3 related disorders. Behavioural Brain Research, 2017, 328, 218-226.	1.2	16
38	Do repetitive <scp>V</scp>alsalva maneuvers reduce glymphatic clearance?. Annals of Neurology, 2017, 81, 322-322.	2.8	3
39	Non human primate models for Alzheimerâ€™s disease-related research and drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 187-200.	2.5	50
40	Adapted Morris Water Maze protocol to prevent interference from confounding motor deficits on cognitive functioning. Somatosensory & Motor Research, 2017, 34, 172-178.	0.4	8
41	Evidence for the existence of a communication between the eye and the brain?. Acta Neurochirurgica, 2017, 159, 1413-1414.	0.9	2
42	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. Neurobiology of Disease, 2017, 105, 235-244.	2.1	14
43	The two faces of the translaminar pressure difference: the biomechanical one and the biochemical one. Australasian journal of optometry, The, 2017, 100, 102-103.	0.6	2
44	Aging, microglia and cytoskeletal regulation are key factors in the pathological evolution of the APP23 mouse model for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 395-405.	1.8	9
45	Increased White Matter Inflammation in Aging- and Alzheimerâ€™s Disease Brain. Frontiers in Molecular Neuroscience, 2017, 10, 206.	1.4	136
46	â€œHypodense Holesâ€•and the Ocular Glymphatic System: Author Response: â€œBlack Holesâ€•and the Ocular Glymphatic System. , 2017, 58, 1132.		1
47	The Glymphatic Hypothesis of Glaucoma: A Unifying Concept Incorporating Vascular, Biomechanical, and Biochemical Aspects of the Disease. BioMed Research International, 2017, 2017, 1-7.	0.9	1,089
48	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. Current Alzheimer Research, 2016, 13, 1145-1164.	0.7	50
49	The Glymphatic System: A New Player in Ocular Diseases?. , 2016, 57, 5426.		42
50	A General Decline in Cerebrospinal Fluid Flow. Journal of Neuro-Ophthalmology, 2016, 36, 227-228.	0.4	0
51	A general decline in cerebrospinal fluid flow and optic nerve compartmentation: are these sequential steps leading to toxicity in normalâ€tension glaucoma?. Acta Ophthalmologica, 2016, 94, e242-3.	0.6	2
52	Fast circulation of cerebrospinal fluid: an alternative perspective on the protective role of high intracranial pressure in ocular hypertension. Australasian journal of optometry, The, 2016, 99, 213-218.	0.6	13
53	Specific Triazine Herbicides Induce Amyloid-Î²42 Production. Journal of Alzheimer's Disease, 2016, 54, 1593-1605.	1.2	14
54	Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimerâ€™s Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. Journal of Alzheimer's Disease, 2016, 55, 763-776.	1.2	39

#	Article	IF	Citations
55	Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 1079-1096.	1.2	33
56	Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 105-112.	1.8	11
57	Age-related macular degeneration, glaucoma and Alzheimerâ€™s disease: amyloidogenic diseases with the same glymphatic background?. Cellular and Molecular Life Sciences, 2016, 73, 4299-4301.	2.4	25
58	Dilated Virchow-Robin spaces in primary open-angle glaucoma: a biomarker of glymphatic waste clearance dysfunction?. Acta Radiologica Open, 2016, 5, 205846011665363.	0.3	2
59	Cerebral and cerebellar language organization in a right-handed subject with a left temporal porencephalic cyst: An fMRI study. Journal of Neurolinguistics, 2016, 37, 41-46.	0.5	0
60	Serum NGAL is Associated with Distinct Plasma Amyloid-Î² Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. Journal of Alzheimer's Disease, 2015, 45, 733-743.	1.2	17
61	A multidisciplinary approach unravels early and persistent effects of X-ray exposure at the onset of prenatal neurogenesis. Journal of Neurodevelopmental Disorders, 2015, 7, 3.	1.5	44
62	A new glaucoma hypothesis: a role of glymphatic system dysfunction. Fluids and Barriers of the CNS, 2015, 12, 16.	2.4	93
63	Glaucoma and the Role of Cerebrospinal Fluid Dynamics. , 2015, 56, 6630.		15
64	Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. NeuroImage, 2015, 109, 151-159.	2.1	32
65	Intracranial pressure fluctuations: a potential risk factor for glaucoma?. Acta Ophthalmologica, 2015, 93, e83-e84.	0.6	8
66	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 7.	3.0	47
67	Impaired gait pattern as a sensitive tool to assess hypoxic brain damage in a novel mouse model of atherosclerotic plaque rupture. Physiology and Behavior, 2015, 139, 397-402.	1.0	15
68	Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. MethodsX, 2015, 2, 112-123.	0.7	19
69	The GABA_A receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle, 2015, 14, 2985-2995.	1.3	87
70	Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. Neurobiology of Disease, 2015, 82, 526-539.	2.1	69
71	Behavioural and psychological symptoms ofÂdementia in Down syndrome: Early indicators ofÂclinical Alzheimer's disease?. Cortex, 2015, 73, 36-61.	1.1	201
72	Glaucoma Considered as an Imbalance Between Production and Clearance of Neurotoxins. , 2014, 55, 5351.		23

#	Article	IF	Citations
73	Psychiatric Disorders in Dementia. , 2014, , 271-324.		1
74	Animal Models for Brain Research. , 2014, , 3-46.		0
75	Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. Journal of Chromatography A, 2014, 1353, 28-39.	1.8	36
76	The role of low intracranial pressure in the development of glaucoma in patients with Alzheimer's disease. Progress in Retinal and Eye Research, 2014, 39, 107-110.	7.3	8
77	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2691-2700.	1.5	70
78	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 819-833.	1.2	53
79	Serum MHPG Strongly Predicts Conversion to Alzheimer's Disease in Behaviorally Characterized Subjects with Down Syndrome. Journal of Alzheimer's Disease, 2014, 43, 871-891.	1.2	32
80	Senescent Changes in Cerebrospinal Fluid Circulatory Physiology and Their Role in the Pathogenesis of Normal-tension Glaucoma. American Journal of Ophthalmology, 2013, 156, 5-14.e2.	1.7	52
81	A behavioural study of neuroglobin-overexpressing mice under normoxic and hypoxic conditions. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1764-1771.	1.1	13
82	Aripiprazole in the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2013, 14, 459-474.	0.9	46
83	Neuropeptides in Alzheimer`s Disease: From Pathophysiological Mechanisms to Therapeutic Opportunities. Current Alzheimer Research, 2013, 10, 449-468.	0.7	15
84	Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behavioural Brain Research, 2012, 229, 244-249.	1.2	109
85	Cellular ageing, increased mortality and FTLDâ€TDPâ€associated neuropathology in progranulin knockout mice. Journal of Pathology, 2012, 228, 67-76.	2.1	102
86	Behavioral Validation in Animal Models of Dementia. Neuromethods, 2011, , 143-154.	0.2	1
87	Genes Involved in Cerebrospinal Fluid Production as Candidate Genes for Late-Onset Alzheimer's Disease: A Hypothesis. Journal of Neurogenetics, 2011, 25, 195-200.	0.6	13
88	Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	1.1	25
89	Region- and Age-Specific Changes in Glutamate Transport in the AÎ²PP23 Mouse Model for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 287-300.	1.2	100
90	Animal models in the drug discovery pipeline for Alzheimer's disease. British Journal of Pharmacology, 2011, 164, 1285-1300.	2.7	180

#	Article	IF	Citations
91	Morphological changes in the enteric nervous system of aging and APP23 transgenic mice. Brain Research, 2011, 1378, 43-53.	1.1	37
92	Comparison of extraction methods for peptidomics analysis of mouse brain tissue. Journal of Neuroscience Methods, 2011, 197, 231-237.	1.3	16
93	APP-Based Transgenic Models: The APP23 Model. Neuromethods, 2011, , 399-413.	0.2	0
94	General Introduction to Animal Models of Human Conditions. Neuromethods, 2011, , 3-13.	0.2	0
95	Species, Strain, and Gender Issues in the Development and Validation of Animal Models of Dementia. Neuromethods, 2011, , 53-75.	0.2	2
96	Adeno-associated Virus Gene Therapy With Cholesterol 24-Hydroxylase Reduces the Amyloid Pathology Before or After the Onset of Amyloid Plaques in Mouse Models of Alzheimer's Disease. Molecular Therapy, 2010, 18, 44-53.	3.7	166
97	Excitatory amino acids and monoaminergic neurotransmitters in cerebrospinal fluid of acute ischemic stroke patients. Neurochemistry International, 2010, 56, 865-870.	1.9	21
98	Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. Regulatory Peptides, 2009, 156, 77-82.	1.9	34
99	Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice. Neuroscience Letters, 2009, 463, 93-97.	1.0	14
100	Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimerâ€™s disease. Psychopharmacology, 2008, 197, 37-43.	1.5	41
101	Intraneuronal amyloid Î² and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. Neurobiology of Aging, 2008, 29, 241-252.	1.5	52
102	Evaluation of the APP23-model for Alzheimer's disease in the odour paired-associate test for hippocampus-dependent memory. Behavioural Brain Research, 2008, 190, 147-151.	1.2	14
103	Validation of the APP23 Transgenic Mouse Model of Alzheimerâ€™s Disease through Evaluation of Risperidone Treatment on Aggressive Behaviour. Arzneimittelforschung, 2008, 58, 265-268.	0.5	9
104	Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model.. Behavioral Neuroscience, 2008, 122, 491-497.	0.6	45
105	Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. Behavioural Brain Research, 2007, 180, 146-151.	1.2	34
106	Cognitive evaluation of disease-modifying efficacy of Galantamine and Memantine in the APP23 model. European Neuropsychopharmacology, 2006, 16, 59-69.	0.3	68
107	APP23 mice display working memory impairment in the plus-shaped water maze. Neuroscience Letters, 2006, 407, 6-10.	1.0	21
108	Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. Neurobiology of Learning and Memory, 2006, 85, 164-172.	1.0	86

#	Article	IF	Citations
109	Aggressive male APP23 mice modeling behavioral alterations in dementia.. Behavioral Neuroscience, 2006, 120, 1380-1383.	0.6	31
110	Drug discovery in dementia: the role of rodent models. Nature Reviews Drug Discovery, 2006, 5, 956-970.	21.5	189
111	Decreased expression of the GABAA receptor in fragile X syndrome. Brain Research, 2006, 1121, 238-245.	1.1	297
112	Actigraphic measurement of agitated behaviour in dementia. International Journal of Geriatric Psychiatry, 2006, 21, 388-393.	1.3	55
113	Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Human Molecular Genetics, 2006, 15, 53-64.	1.4	80
114	APP23 Mice as a Model of Alzheimer's Disease: An Example of a Transgenic Approach to Modeling a CNS Disorder. CNS Spectrums, 2005, 10, 207-222.	0.7	51
115	Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology, 2005, 180, 177-190.	1.5	119
116	Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochemistry International, 2005, 46, 409-422.	1.9	39
117	Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behavioural Brain Research, 2005, 162, 233-239.	1.2	117
118	GSA: behavioral, histological, electrophysiological and neurochemical effects. Physiology and Behavior, 2005, 84, 251-264.	1.0	16
119	Biochemical and behavioural phenotyping of a mouse model for GAMT deficiency. Journal of the Neurological Sciences, 2005, 231, 49-55.	0.3	33
120	Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. European Journal of Neuroscience, 2004, 20, 2757-2766.	1.2	74
121	Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. European Journal of Neuroscience, 2003, 17, 388-396.	1.2	244
122	Hyperactivity, neuromotor defects, and impaired learning and memory in a mouse model for metachromatic leukodystrophy. Brain Research, 2001, 907, 35-43.	1.1	41
123	Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behavioural Brain Research, 2000, 117, 127-136.	1.2	133